Though one key ingredient is luck, exit-by-M&A can be planned, as the Esperion-Pfizer transaction shows. Focusing on a single underappreciated pathway and eschewing discovery, Esperion put together, very inexpensively and very quickly, an in-licensed portfolio of related compounds. By doing so, Esperion minimized the chances it would find itself competing against an improved follow-on should it prove the value of its mechanism of action. Likewise, once it had reached some clinical proof of principle, its strategy positioned it either for a major multi-product deal or, even more likely, an acquisition-with Pfizer's $1.3 billion takeover the eventual outcome.
By Roger Longman
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.
As the health care industry undergoes a digital transformation, the integration of AI into Quality and Regulatory Management Systems is proving essential. The challenges for successful AI deployment emphasize the need for robust digital infrastructure, data literacy programs and privacy measures to enhance patient safety and commercial performance.
Aurion Biotech is developing a cell therapy for corneal diseases that is cheap enough to produce and can be scaled that it should reach the masses in a way that other cell therapies cannot.
Companies are exploring new mechanisms of action beyond traditional amyloid and tau and both investors and big pharma are willing to make deals when the science is compelling, panelists at Biotech Showcase said.
Ochre Bio co-founder and CSO Quin Wills spoke with In Vivo about the UK-based company's novel approach to finding RNA therapies for chronic liver disease.
As GLP-1 agonists surge to blockbuster status transforming diabetes and obesity treatment, Richard DiMarchi, the pioneering scientist behind their development, recounts the inside story of the drug class in a fireside chat.
João Ribas combines scientific expertise with venture capital at Novo Holdings, applying his dual background to develop biotech investments that connect academic research with commercial opportunity.